Laropiprant

Laropiprant

Identifiers
IUPAC name (-)-[(3R)-4-(4-chlorobenzyl)-7-fluoro-5-(methylsulfonyl)- 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid
CAS Number	571170-77-9
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C21H19ClFNO4S
Molar mass	435.90 g/mol

WikiDoc Resources for Laropiprant
Articles
Most recent articles on Laropiprant Most cited articles on Laropiprant Review articles on Laropiprant Articles on Laropiprant in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Laropiprant Images of Laropiprant Photos of Laropiprant Podcasts & MP3s on Laropiprant Videos on Laropiprant
Evidence Based Medicine
Cochrane Collaboration on Laropiprant Bandolier on Laropiprant TRIP on Laropiprant
Clinical Trials
Ongoing Trials on Laropiprant at Clinical Trials.gov Trial results on Laropiprant Clinical Trials on Laropiprant at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Laropiprant NICE Guidance on Laropiprant NHS PRODIGY Guidance FDA on Laropiprant CDC on Laropiprant
Books
Books on Laropiprant
News
Laropiprant in the news Be alerted to news on Laropiprant News trends on Laropiprant
Commentary
Blogs on Laropiprant
Definitions
Definitions of Laropiprant
Patient Resources / Community
Patient resources on Laropiprant Discussion groups on Laropiprant Patient Handouts on Laropiprant Directions to Hospitals Treating Laropiprant Risk calculators and risk factors for Laropiprant
Healthcare Provider Resources
Symptoms of Laropiprant Causes & Risk Factors for Laropiprant Diagnostic studies for Laropiprant Treatment of Laropiprant
Continuing Medical Education (CME)
CME Programs on Laropiprant
International
Laropiprant en Espanol Laropiprant en Francais
Business
Laropiprant in the Marketplace Patents on Laropiprant
Experimental / Informatics
List of terms related to Laropiprant

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Laropiprant (pINN; codenamed MK-0524A) is an investigational treatment for hypercholesterolemia. It is a prostanoid DP1 receptor antagonist. It will be marketed by Merck & Co. as a combination with niacin and will be sold under the tradenames Cordaptive and Tredaptive.

In October 2008, Merck expanded the THRIVE Trial from 20,000 to 25,000 patients in order to expedite a second bid for FDA approval of its experimental cholesterol drug, MK-0524A. MK-0524A is a combination of niacin and laropiprant, which is aimed at limiting facial flushing associated with niacin. In April 2008 the FDA decided to withhold approval for the experimental drug, deciding to wait until the results of the THRIVE Trial could be analyzed.

Template:Lipid modifying agents

Template:WikiDoc Sources